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Mitral regurgitation (MR) is one of the most prevalent val-vular heart diseases in Western countries. The current 
estimated prevalence of moderate and severe MR in the United 
States is 2 to 2.5 million, and it is expected that this number 
will rise to 5 million by 2030.1 Surgical intervention is recom-
mended for symptomatic severe MR or asymptomatic severe 
MR with left ventricular (LV) dysfunction.2 Treatment of 
degenerative MR has evolved from mitral valve (MV) replace-
ment to MV repair because of superior long-term outcomes 
after repair.2–4 For functional MR, however, the benefit over 
MV replacement is less certain.5 In addition, minimally inva-
sive MV surgery has become a well-established and increas-
ingly used option for managing patients with MV pathology.6
Although surgery remains the gold standard treatment for 
significant MR, MV surgery is deferred in a large number of 
patients because of high surgical risk.7 The decrease in the 
prevalence of rheumatic valve disease, in combination with an 
increased life expectancy, has led to a high prevalence of degen-
erative MR. As a consequence, patients are older and present 
with comorbidities that increase operative mortality and mor-
bidity risks.8 In octogenarians, there has been reported a mor-
tality and morbidity rate of 17.0% and 35.5%, respectively, 
following MV surgery.9 This results in denial or nonreferral for 
surgery in a large group of patients with significant MR—the 
Euro Heart Survey revealed that up to 50% of patients hospi-
talized with symptomatic severe MR are not referred for MV 
surgery, mainly because of advanced age, comorbidities, and 
LV dysfunction. In patients aged ≥80 years, surgical treatment 
was performed in only 15% compared to 60% in patients aged 
≤70 years.8,10
The observation that a significant number of patients are 
not referred for MV surgery and the desire for less invasive 
approaches have led to the development of different percuta-
neous approaches aiming at treating MR.
Transcatheter MV Repair
During the past few years, several percutaneous transcatheter 
MV repair (TMVR
e
) technologies have emerged as possible 
alternatives to open surgery for high-risk patients, and these 
technologies are currently at different stages of investigation 
and clinical implementation. A classification of percutaneous 
TMVR
e
 technologies on the basis of anatomic targets is pro-
posed and groups the devices into those targeting the follow-
ing: (1) leaflets: percutaneous leaflet plication (edge-to-edge 
MV repair), leaflet coaptation, leaflet ablation; (2) annulus: 
indirect annuloplasty through the coronary sinus or direct 
annuloplasty (true percutaneous or by hybrid approach); (3) 
chordae: percutaneous chordal implantation; or (4) LV: percu-
taneous LV remodeling.11
The device with the largest clinical experience is the 
MitraClip system (Abbott Laboratories, IL) using the edge-
to-edge clip technique for percutaneous MV repair. The 
EVEREST (Endovascular Valve Edge-to-Edge Repair Study) 
II study is the only randomized controlled trial with pub-
lished data comparing MitraClip therapy with conventional 
surgery in degenerative MR. One-year results showed that 
percutaneous MV edge-to-edge repair was less effective than 
surgery in reducing MR but that it was associated with supe-
rior safety and similar improvements in clinical outcome.12  
At 4-year follow-up, patients treated with the MitraClip sys-
tem were reported to require more frequently MV surgery to 
treat residual MR compared with the surgical group, although 
no differences were observed after 1-year follow-up. In addi-
tion, there were no differences in the prevalence of (moderate)-
severe MR or mortality at 4-year follow-up.13 As a result, the 
MitraClip system obtained approval from the US Food and 
Drug Administration in 2013 for patients with significant 
symptomatic degenerative MR who are at prohibitive risk for 
MV surgery. Trials studying the role of the MitraClip system 
in patients with symptomatic functional MR are still ongoing.
The other percutaneous TMVR
e
 technologies using the con-
cepts of annuloplasty, chordal implantation, and LV remod-
eling are still under development, and although safety rates 
have generally been equal or superior to conventional surgery, 
efficacy has been suboptimal.11,14 In the future, multiple per-
cutaneous repair techniques may be used in combination to 
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increase overall efficacy.11 However, for many patients MV 
repair will not be possible, and MV replacement will be 
required. Further limitations of TMVR
e
 are unequal tension 
on left atrium or mitral annulus (coronary sinus at a distance 
from annulus) when using coronary sinus reshaping devices, 
as well as the possibility of iatrogenic mitral stenosis.11
Transcatheter MV Replacement
Transcatheter valve replacement for the treatment of diseased 
heart valves in selected patients is of increasing importance, 
with promising results after transcatheter aortic valve replace-
ment.15–17 The performance of transcatheter aortic valve 
replacement has rapidly increased in the past few years—the 
number of procedures in Europe more than tripled in recent 
years, from 4500 in 2009 to >18 000 in 2011 (>50% of these 
were performed in ocotgenarians).18 In accordance, transcathe-
ter MV replacement (TMVR) may have the potential to become 
an alternative to treat severe MR in patients who are at high 
surgical risk because of its theoretical possibility to reduce MR 
to a similar extent as surgery while reducing procedural risks. 
Furthermore, TMVR could offer a wider applicability across 
patient and disease variations compared with TMVR
e
 and can 
be made into a rather simple and fast procedure.
The feasibility of this approach has been reported for 
TMVR with the SAPIEN XT valve (Edwards, CA) and 
Melody valve (Medtronic, MN) in dysfunctional mitral 
bioprostheses and annuloplasty rings. These percutaneous 
valve-in-valve and valve-in-ring implantations of transcath-
eter heart valves have shown excellent hemodynamic per-
formance with low transvalvular gradient and perivalvular 
regurgitation.19–24 In February 2014, Edwards received CE 
Mark approval for transcatheter mitral valve-in-valve pro-
cedures using the SAPIEN XT valve. Furthermore, 3 recent 
case reports described successful TMVR using balloon-
expandable transcatheter heart valves in patients with a 
severely calcified native MV stenosis, indicating that MV 
disease with a calcified annulus may be treated with TMVR 
in selected high-risk patients.25–27
The data showing that MV disease is undertreated world-
wide coupled with the large number of patients not eligible for 
TMVR
e
 has driven the field of percutaneous TMVR. However, 
many challenges need to be addressed in the design of a device 
that targets the most complex of the heart’s 4 valves.28,29 These 
challenges for TMVR devices are discussed more exten-
sively in Table 1. Ideally, TMV implants should restore uni-
directional flow while minimizing the risks associated with 
Table 1. Challenges for Percutaneous TMVR Devices
Valve position
 To be deployed in the left AV position, making a truly percutaneous, transfemoral delivery a challenge—because of the requirement for transseptal (or transaortic 
retrograde) access to the LA or LV and the need for a multidimensional, highly curved catheter course (which is challenging with a large delivery system and limits 
the precision with which tension and traction are transmitted to the operating end of the system)
  Possible access routes: transapical, transseptal, transatrial
Valve anatomy
  Should fit an asymmetrical saddle-shaped mitral annulus
  There is no stable calcified structure for anchoring (unlike for TAVR) in most cases*
  The mitral valve is a complex structure composed of leaflets, annulus, chordae tendineae, and papillary muscles—preservation of the subvalvular apparatus is 
mandatory to preserve LV geometry
  There is an irregular geometry of the mitral valve leaflets
Dynamic environment
  There are dynamic changes in mitral annular geometry (shape/size) during the cardiac cycle, resulting in an overall reduction of annular area up to 30% and a 
reduction of annular circumference of up to 15%30
  The device should be resistant to displacement or migration while enduring continuous cyclic movements of the annulus and LV base, as well as high transvalvular 
gradients (high dislodgment forces)
Device requirements
  The device should have a balanced radial stiffness to resist the dynamic environment and avoid frame fracture, whereas at the same time its stiffness should not 
cause perforation of adjacent structures.
  Valve materials must be durable enough to withstand the loads generated
  The device should not obstruct the left ventricular outflow tract, occlude the circumflex coronary artery, compress the coronary sinus, or cause major conduction 
system disruption
  Because of the large annular size, there is a need for large delivery systems
Hemodynamic performance
  Paravalvular leak (PVL) should be minimized because regurgitation is poorly tolerated in the mitral position as a result of the higher pressure gradient across the 
valve. Moreover, PVL may result in hemolysis.
  The TMVR should restore unidirectional flow while minimizing the risks associated with the procedure
Other issues
  Thrombogenicity of a bulky device implanted in the left AV position
  Possibility of reoperation or TMVR-in-TMVR is still unclear
AV indicates atrioventricular; LA, left atrium; LV, left ventricle; TAVR, transcatheter aortic valve replacement; and TMVR, transcatheter mitral valve replacement.
*In some patients with mitral valve stenosis, it is possible to anchor the device in the severely calcified mitral annulus.25–27
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the procedure, allowing high-risk and inoperable patients to 
receive definitive treatment.
This review aims to give an overview of the different per-
cutaneous TMVR technologies currently under development. 
We report a list that is complete to the best of our knowl-
edge. All manufacturers were asked to provide information 
on valve design and (pre)clinical results—this information 
was integrated with data available in peer-reviewed journals 
as well as with information provided by the coauthors that 
was not published before. Many of the device specifications 
and image material are published here for the first time; still 
some information could not be provided because of confi-
dentiality reasons.
CardiAQ Valve
Device
The CardiAQ valve (CardiAQ Valve Technologies, CA) con-
sists of a self-expanding nitinol frame, which carries 3 leaflets 
of bovine pericardial tissue. The device is designed in such a 
way that it does not use radial force for fixation to the annulus. 
Two sets of anchors grasping the mitral leaflets from the left 
atrial and LV side are used for fixation of the valve prosthesis. 
In addition, foreshortening of the frame creates a clamping 
action that anchors the valve above and below the annulus. 
The chordae and papillary apparatus should normally be 
preserved (Figure 1A). The different steps of valve deploy-
ment should be well controllable, and the fact that the valve is 
designed to be repositionable before final deployment should 
help ensure accurate placement (Figure 1B–1F). The device 
can be inserted truly percutaneously through the femoral vein 
using a transseptal access to the left atrium (antegrade). Alter-
native access is a transapical approach (retrograde).
Preclinical Development
Preclinical assessment of safety and feasibility of the Car-
diAQ valve has been successful. Animal experiments were 
conducted in 20 swine. A correct implantation position was 
obtained in 14 of 19 animals, whereas an infra- and supra-
annular implant was observed in 4 and 1 animal(s), respec-
tively. One animal was lost before initiating the procedure. 
None of the valves migrated or embolized after implanta-
tion. Successful implantation resulted in an excellent TMV 
function and stable hemodynamics, with no LV outflow tract 
(LVOT) obstruction, coronary artery obstruction, or transval-
vular gradient (unpublished data, presented at TCT 2012 by 
L. Søndergaard).
First-In-Human
A milestone was achieved on June 12, 2012, when the first-
in-human TMVR was conducted at Rigshospitalet, Copenha-
gen, Denmark. The patient, a 86-year-old man experiencing 
symptomatic severe MR grade IV+, was declined for MV 
surgery and MitraClip treatment. With the use of an ante-
grade transseptal approach, a CardiAQ valve was successfully 
implanted, resulting in an accurate and stable position. The 
first 24 hours, the patient made an uneventful recovery and 
was hemodynamically stable. However, despite a well-func-
tioning TMV prosthesis, the patient died 3 days postprocedure 
because of multiorgan failure (unpublished data, provided by 
L. Søndergaard).
Tiara Valve
Device
The Tiara valve (Neovasc Inc, British Columbia, Canada) is 
a self-expanding bioprosthesis with cross-linked bovine peri-
cardial tissue leaflets mounted inside a metal alloy frame. The 
atrial portion is designed specifically to fit the saddle-shaped 
mitral annulus; the D shape should match the natural shape of 
the mitral orifice and prevent impingement of the LVOT. The 
ventricular portion of the device comprises a covered skirt to 
prevent paravalvular leakage (PVL), as well as 3 anchoring 
structures. The 2 anterior anchoring structures are designed 
to capture the fibrous trigones at both sides of the anterior 
MV leaflet, whereas the posterior anchoring structure proj-
ects behind the posterior MV leaflet, thus creating a 3-point 
Figure 1. CardiAQ valve. A, The valve consists of a self-expand-
ing nitinol frame that carries 3 leaflets of bovine pericardial 
tissue. Implantation sequence of CardiAQ valve: (B) coaxial align-
ment, (C) opening of the ventricular anchors, (D) opening of the 
atrial anchors, and (E) final release of the CardiAQ valve before 
removal of the delivery system. F, Left ventriculogram show-
ing good position of the transcatheter mitral valve prosthesis 
and absence of significant mitral regurgitation. A, Image was 
provided by and is the property of CardiAQ Valve Technologies, 
Inc. Printed with permission. B–F, Images courtesy of Dr Sønder-
gaard. Printed with permission.
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anchor on the ventricular side that works in conjunction 
with the atrial flange to secure the prosthetic valve within 
the mitral annulus. This securement should prevent retro-
grade dislodgment during systole (Figure 2).28,31 In all stages, 
until the final step of ventricular deployment, the Tiara valve 
should be fully retrievable and repositionable. Implantation is 
performed transapically by means of a 32F delivery catheter 
and should not require rapid pacing (Figure 2).
Preclinical Development
Preclinical assessment of safety and feasibility of the Tiara 
valve has been successful.28 This included both acute and 
chronic animal models, as well as human cadavers. In 
the acute animal model, Tiara valves were successfully 
implanted in 29 of 36 (81%) swine. Implantation was 
unsuccessful in 7 animals because of improper position-
ing of the valve (n=3), failure of the valve anchors (n=2), 
and ventricular fibrillation (n=2). None of the valves 
migrated or embolized after implantation. There was a 
steady increase in the rate of successful implantation as the 
series progressed, with the final 12 animals all undergo-
ing successful and uneventful implantation. Both acute and 
chronic evaluation demonstrated excellent valve function 
and alignment, with no LVOT obstruction, coronary artery 
obstruction, or transvalvular gradient. Chronic evaluation 
of 7 sheep demonstrated clinically stable animals through-
out a follow-up of 150 days. The investigators attribute a 
relatively high rate of PVL observed in the chronic ani-
mal model to the fact that only one size of the Tiara valve 
was available, making size mismatch between the native 
Figure 2. Tiara valve. A, The D-shape of the valve, the atrial 
skirt that engages the atrial aspect of the mitral annulus, and the 
saddle-shaped valve are clearly seen. B, Transapical 32F delivery 
system. Implantation sequence of Tiara valve: (C) the coronary 
sinus wire outlines the mitral annulus; the pigtail catheter is ante-
riorly in the ascending aorta, and the delivery system is through 
the mitral annulus into the left atrium; (D) opening of the atrial 
skirt in the left atrium and the flat aspect of the D-shaped Tiara 
are facing anteriorly; (E) the atrial skirt is open and positioned on 
the atrial aspect of the mitral annulus, and the ventricular por-
tion of the Tiara valve is delivered into position just before final 
release; (F) final release of the Tiara valve, before removal of the 
delivery system. Reprinted from Banai et al28 with permission of 
the publisher. Copyright ©2014, American College of Cardiology 
Foundation.
Figure 3. Tendyne valve. A, The valve consists of a self-
expanding metal alloy frame made of an inner stent containing a 
trileaflet porcine pericardial valve and an outer stent that abuts 
the native mitral annular tissues. The device is secured in place 
using a polymer tether that passes through the left ventricle 
to an epicardial pad. Implantation sequence: (B) access of left 
atrium with dilator and sheath; (C) advancement of valve within 
sheath, deploying valve in left atrium; tether traction is used to 
position the valve in native annulus; (D) the polymer tether allows 
the valve to be captured for repositioning or replacement with 
alternative valve size, if necessary; (E and F) left ventriculogram 
showing elimination of severe mitral regurgitation in human 
subject. These images were provided by and are the property of 
Tendyne Inc. Printed with permission.
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annulus and prosthetic device unavoidable in many hearts. 
In situ cardioscopy showed homogeneous coverage of the 
metal struts with a white fibrotic connective tissue layer, 
both along the atrial and ventricular struts. Macroscopic 
and microscopic evaluation demonstrated that devices 
seemed well seated, and all valve frames showed good 
incorporation by a thin pannus around the atrial and ven-
tricular surfaces with fibrous tissue growth adequate for 
healing. The pericardial leaflets were intact without tears or 
perforations. The human cadaver model demonstrated that 
implantation resulted in appropriate geometric positioning 
with full circumferential coverage of the atrial aspect of 
the mitral annulus and good apposition and location of the 
ventricular anchoring system.28
First-In-Human
The first 2 cases of human Tiara valve implantation were 
performed in January and February 2014 at St. Paul’s Hospi-
tal, Vancouver, British Columbia, Canada. Both patients had 
severe functional MR, poor LV function, and were considered 
extremely high-risk candidates for conventional MV surgery. 
The transapical procedures resulted in immediate elimination 
of MR and improved LV stroke volumes, without the need 
for any cardiac support device and with no procedural com-
plications (unpublished data, provided by manufacturer). The 
further outcome was kept confidential.
Tendyne Valve
Device
The Tendyne valve (Tendyne Inc, MN) is a trileaflet pericar-
dial valve sewn onto a nitinol frame (Figure 3A). Because 
the valve is a descendant of the Lutter valve, the Tendyne 
valve shares several design elements with the Lutter valve: 
(1) an atrial fixation system, (2) a ventricular body made of 
a nitinol self-expanding stent frame that accommodates a 
bioprosthetic heart valve, and (3) a ventricular fixation sys-
tem composed of tethering strings attached to the stent. The 
Tendyne valve is designed to be fully retrievable, and precise 
deployment and accurate adjustment of its intra-annular posi-
tion should be achievable to minimize the risk of PVL. The 
prosthetic valve is delivered transapically and is secured via 
a tether (neochordae) near the LV apex using a pad that sits 
on the epicardium.
Preclinical Development
The Lutter valve has been successfully implanted in several 
acute and chronic porcine models, with follow-up times of 
up to 2 months.32–39 During first studies, 30 pigs underwent 
off-pump mitral valved stent implantation with follow-
up times of 60 minutes and 7 days. Accurate positioning 
was established in all but 5 animals. There were no issues 
of device migration, embolization, or LVOT obstruction. 
These studies proved the feasibility of reproducible deploy-
ment of the Lutter valve, achieving reliable prosthesis sta-
bility and adequate valve function in acute and short-term 
experimental settings. However, stent mal-deployment and 
fracture were 2 of the main complications seen throughout 
this study.36
In a more recent study, adequate valve deployment and 
function were obtained in all but 1 animal with a newer pro-
totype of the Lutter valve (n=6). Mild regurgitation devel-
oped after valve deployment in 1 animal just after 1 hour and 
in none thereafter. The average gradients across the valve 
Figure 4. Medtronic transcatheter mitral valve.  
A, The bioprosthetic valve is a trileaflet pericardial 
valve—it has support arms that function to cap-
ture the anterior and posterior mitral valve leaflet 
and engage the submitral apparatus. B, The con-
cept of axial fixation using the mitral apparatus 
to secure the device in position. C, Acute animal 
results showing good positioning with no central 
or paravalvular leak. D, Preservation of the submi-
tral apparatus and no left ventricular outflow tract 
obstruction. Images courtesy of Dr Piazza. Printed 
with permission.
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and LVOT were low. All animals exhibited normal hemo-
dynamics, and stability was maintained during follow-up. 
Migration, embolization, and PVL were not evident in the 
remaining animals after 4 and 8 weeks. Gross evaluation 
revealed that 50% to 70% of the atrial element was covered 
by tissue growth at 4 to 8 weeks.37
An additional study focused on the evaluation of 2 dif-
ferent frame designs: (1) the first design consisted of a 
circular crown-shaped atrial element connected to a tube-
shaped ventricular element, and (2) in the second design, 
this atrial element was D-shaped to achieve better ana-
tomic alignment. Although in vitro testing showed less 
PVL in the antero medial region in D-shaped design stents, 
animal tests showed less favorable results, with rotational 
reorientation of all stents with D-shaped elements causing 
more severe PVL and preventing these advantages to take 
effect. Clearly, more studies are warranted to clarify this 
issue.38,39
First-In-Human
The first 2 cases of human Tendyne valve implantation were 
performed in patients going to surgical MV replacement at 
the French Hospital, Asuncion, Paraguay (2013). The trans-
apical procedure resulted in elimination of MR grade IV in 
one patient and reduction of MR grade IV to grade I in the 
other patient (unpublished data, provided by manufacturer). 
The further outcome was kept confidential.
Medtronic—TMV
Device
Medtronic’s TMV is a trileaflet pericardial valve, optimized 
for the mitral position. The bioprosthetic valve features a large 
inflow atrial portion that is responsible for sealing and a short 
outflow ventricular portion to avoid LVOT obstruction. It has 
support arms that function to capture the anterior MV leaflet/
Figure 5. Valtech’s Cardiovalve is a transcatheter mitral valve 
replacement system designed to be implanted using the transfemo-
ral route. The implantation procedure is a 2-step approach: the first 
step involves implanting a sealing polyester skirt, and the second 
step is the implantation of the valve. These images were provided by 
and are the property of Valtech Cardio Ltd. Printed with permission.
Figure 6. HighLife transcatheter mitral valve replacement system. The implantation procedure is a 2-step approach: A and B, The first 
step encompasses the placement of a locking component in the subannular space, using a transfemoral (transaortic) route; (C–F) the 
second step is the implantation of the Highlife valve over a transatrial access—on deployment of the stent-valve, the locking compo-
nent automatically contacts the preformed groove in the stent-valve, creating a reliable anchoring and sealing mechanism in the annular 
region. G, Left ventriculogram showing good position of the Highlife valve and absence of mitral regurgitation. H, Transesophageal echo-
cardiography (3D) image showing the trileaflet transcatheter mitral valve bioprosthesis during systole. These images were provided by 
and are the property of HighLife Medical. Printed with permission.
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posterior MV leaflet and engage the submitral apparatus. The 
device is designed in such way that it should not rely on out-
ward radial forces for anchoring; instead, it uses the mitral 
apparatus for axial fixation (Figure 4). The valve is designed 
to be fully retrievable and it should be possible to refold and 
withdraw the valve via a catheter in case a bailout procedure 
is needed. The current device is delivered transatrially, similar 
to a minimally invasive MV repair, with transseptal delivery 
under development.
Preclinical Development
In acute animal studies, Medtronic’s TMV has been success-
fully implanted, resulting in accurate and stable valve posi-
tioning. Implantations were performed using a combination of 
fluoroscopic and echocardiographic guidance, combined with 
some tactile feedback when pulling on the catheter to engage 
the support arms under the A2-P2 leaflet segments. There was 
absence of central and paravalvular leakage, LVOT obstruc-
tion, and transvalvular gradients (unpublished data, presented 
at EuroPCR 2013 by N. Piazza).
FORTIS Valve
Device
The FORTIS TMV (Edwards Lifesciences Corp, CA) is 
composed of bovine pericardial tissue, a cloth-covered self-
expanding frame designed to minimize PVL, and an anchor-
ing system. The implantation is performed transapically.
First-In-Human
Edwards Lifesciences Corp announced on March 6, 2014, 
in a press release the successful completion of the first-
in-human implants of its FORTIS transcatheter heart valve 
at St. Thomas’ Hospital, London, UK (2014). The TMV 
was implanted transapically to treat 3 patients with severe 
MV disease and many risk factors that prevented them 
from undergoing surgery (unpublished data, provided by 
manufacturer). More detailed information is currently not 
available.
Cardiovalve
The Cardiovalve (Valtech Cardio Ltd, Or Yehuda, Israel) is a 
TMV prosthesis, designed to achieve fixation without radial 
force on the mitral annulus, yet obtaining full sealing and 
freedom from LVOT obstruction. The device is intended to be 
implanted using the transfemoral route. The implantation pro-
cedure is a 2-step approach: the first step involves implanting 
a sealing polyester skirt, and the second step is the implanta-
tion of the valve (Figure 5). This 2-step approach should sim-
plify the procedure and minimize the delivery system profile 
to 26F, thereby enabling transseptal crossing (unpublished 
data, provided by manufacturer). More detailed information is 
currently not available.
Highlife Medical—TMV
Device
HighLife Medical (CA) is developing a TMVR system 
based on the interaction of 2 components. Using a trans-
femoral approach, a locking component should be inserted 
in the LV and placed around the native mitral leaflets close 
to the annulus. Next, a stent valve should be deployed 
between the leaflets over a transatrial access. A dedi-
cated groove in the stent-valve shape should automatically 
engage with the locking component and, in this way, create 
a consistent anchoring and sealing in the annular region 
(Figure 6).
Figure 7. The Endovalve system is a foldable nitinol structure 
that is designed to conform to the mitral annulus and attaches 
to the native valve with specially designed grippers. The original 
Endovalve system is being redesigned to take advantage of 
MID’s Permaseal technology to facilitate a transapical approach. 
Images courtesy of Dr Herrmann. Printed with permission.
Figure 8. The Gorman device. A and B, This sutureless mitral 
valve replacement device consists of a frame constructed from 
a single nitinol wire that is woven into a complex 3-dimensional 
geometry engineered to provide a housing for the valve mecha-
nism and anchoring forces to ensure secure position within 
the mitral annulus: (A) the device as seen from the side; (B) the 
device as seen from the ventricular side. The valve leaflets are 
constructed from porcine pericardium. C and D, Angiographic 
assessment of the Gorman device showing (C) the transcatheter 
mitral valve device is securely anchored and well functioning, 
without mitral regurgitation (MR) or left ventricular outflow tract 
(LVOT) obstruction, and (D) no aortic valve insufficiency. Cx indi-
cates circumflex coronary artery; LA, left atrium; LAD, left anterior 
descending artery; LV, left ventricle; RCA, right coronary artery; 
and SMV, sutureless mitral valve. Reprinted from Gillespie et al40 
with permission of the publisher. Copyright © 2013, The Society 
of Thoracic Surgeons.
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Preclinical Development
Acute animal studies were reported to have shown adequate 
valve function and reproducibility (unpublished data, provided 
by manufacturer). More detailed information is currently not 
available.
Endovalve
Device
Micro Interventional Devices (MID; Newtown, PA) acquired 
Endovalve, Inc—a spin-off from the University of Pennsylva-
nia developing a TMV device based on patented technology 
from Dr Herrmann—in 2011. The Endovalve system was one 
of the earliest conceived designs, intended to improve on the 
limited efficacy of percutaneous repair technologies available 
in 2002. It is a foldable nitinol structure designed to conform 
to the anatomy of the mitral annulus and attach to the native 
valve with specially designed grippers (Figure 7). Although 
more detailed product specifications are not provided, MID 
reports that the Endovalve system is intended to be valve-spar-
ing (subvalvular apparatus) and should provide a leak-proof 
MV replacement with no risk of LVOT obstruction.11
The original Endovalve system is being redesigned to take 
advantage of MID’s Permaseal technology to facilitate a trans-
apical approach. The Permaseal system is a novel transapical 
access and closure device that combines soft-tissue anchors 
with advanced biocompatible elastomers to provide sponta-
neous (sutureless) wound closure after structural heart repair 
procedures.
Preclinical Development
Acute animal experiments were reported to be successful. A 
prototype of the Endovalve system functioned successfully for 
>30 minutes after implantation in 4 sheep (unpublished data, 
provided by manufacturer).
Gorman—TMV
Device
The TMV device designed by Gorman Cardiovascular 
Research Group (University of Pennsylvania, PA) is composed 
of a custom-designed nitinol framework and a pericardial 
leaflet valve mechanism (Figure 8). The frame is constructed 
from a single nitinol wire woven into a complex 3D-shape: the 
flexibility of this nitinol wire-weave stent body design should 
allow the device to gently conform to the complex MV geom-
etry, creating a perivalvular seal without impingement on the 
Figure 9. MitrAssist’s valve-in-valve: a valve that assists the exist-
ing valve. A and B, The MitrAssist device consists of a nitinol frame 
with pericardium tissue and an asymmetrical bileaflet design. C 
and D, The device can be delivered through a low profile catheter 
(18Fr) via a transfemoral, transaortic route. E and F, The MitrAssist 
device should be suitable for almost all types of mitral regurgita-
tion and has a low risk of left ventricular outflow tract obstruction. 
According to MitrAssist Medical, >90% of closure distance is 
promoted by the native leaflets and >80% of LV pressure is acting 
on the native valve apparatus. These images were provided by and 
are the property of MitrAssist Medical Ltd. Printed with permission.
Table 2. Overview of the Different TMVR Devices
Nitinol Frame Trileaflet Approach Delivery System Acute Animal Chronic Animal First-In-Human
 CardiAQ + + T-fem/T-ap 32F + + +
 Tiara + + T-ap 32F + + +
 Tendyne + + T-ap 30F + + +
 Medtronic + + T-atr NA + + −
 FORTIS + + T-ap NA NA NA +
 Cardiovalve + + T-fem 26F + − −
 HighLife + + T-atr NA + − −
 Endovalve + + T-ap NA + − −
 Gorman + + T-atr 30F + − −
 MitrAssist + − T-ao 18F + + −
NA indicates not available; T-ao, transaortic; T-ap, transapical; T-atr, transarterial; T-fem, transfemoral; and TMVR, transcatheter mitral valve replacement.
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LVOT. The TMV device does not solely rely on radial force 
for anchoring strength. Anchoring is facilitated by a combina-
tion of gentle radial expansion and grasping arms that emanate 
from the ventricular aspect of the stent; these arms have been 
designed to insinuate themselves around the leaflets and chor-
dae when the device is exposed to systolic LV pressures.40
Preclinical Development
In acute animal studies, animals underwent on-pump TMVR 
using a left thoracotomy/atriotomy and a 30F delivery system. 
Echocardiographic, angiographic, and hemodynamic evaluation 
revealed normal LV systolic function and no significant PVL, 
LVOT obstruction, or MV stenosis. Necropsy demonstrated that 
the TMV devices were anchored securely. Finally, Gillespie et 
al40 reported the intention to implant this device by means of an 
off-pump, minimally invasive thoracotomy or even a truly percu-
taneous transvenous, transseptal antegrade approach in the future.
MitrAssist
Device
MitrAssist Medical Ltd (Misgav, Israel) has developed an 
approach for the treatment of MR that is neither repair nor 
replacement. Instead, its valve implant is placed on top of the 
native MV with the intention to work in unison with it and to 
enhance valve functionality. The MitrAssist device consists of 
a nitinol frame with pericardium tissue and an asymmetrical 
bileaflet design (Figure 9). The MitrAssist device is designed to 
conform to the native MV’s anatomic shape, preserve the natu-
ral MV functionality, and should have a low risk of migration or 
LVOT obstruction. The device should be repositionable before 
implantation and can be delivered through an 18F catheter.
Preclinical Development
Preclinical studies have been successfully completed in both 
in vitro/ex vivo beating heart and animal experiments. The 
MitrAssist device restored valve functionality in ex vivo beating 
heart experiments in which the native MV was severely damaged. 
A similar restoration of valve functionality was seen in short-
term animal experiments, in which severe MR was successfully 
treated after MitrAssist implantation. In chronic animal studies, 
the device was reported not to jeopardize native MV functioning 
or create hemodynamic disturbances at 35 days postimplant, nei-
ther was there any report of leaflet trauma, adhesion, or thrombus 
formation (unpublished data, provided by manufacturer).
Conclusions
Percutaneous TMVR has proved to be feasible as valve-in-
valve and valve-in-ring procedure in patients at high surgi-
cal risk. Results of animal experiments for TMVR in native 
MV have been encouraging and led the way to first-in-human 
implants, as accomplished with 4 different types of TMV 
devices. Many of the companies report that additional animal 
studies are ongoing or that first or additional human implants 
are anticipated within the current year (Table 2). However, mul-
tiple technical challenges are still to overcome before TMVR 
for native MR will become an option in daily practice. Never-
theless, with ongoing technological advancements in the field 
of transcatheter valve replacement, it may be expected that 
TMVR may become a valuable alternative to MV surgery for 
patients with severe MR and a high surgical risk in the future.
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